In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku[1] executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho (Zeria Pharmaceutical and Cosmetics Laboratory).
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance[2] as of March 2023.
Zeria holds a leading position within the gastroenterology field in Japan.
[3] In 2019, the pain reliever cream EPATEC (ketoprofen) firstly developed by Nissan Chemical Corporation was revocated authorization of Ministry of Health, Labour and Welfare around the contraindications for women in the third trimester of pregnancy.